Literature DB >> 28032900

Cancer prevention in the era of precision oncology.

N N Brahme1,2, E Szabo1.   

Abstract

Cancer is a highly heterogeneous disease, both between and within different target organs. Precision cancer prevention requires understanding the molecular pathways leading to cancer on a "per-person" level, identification of individuals most at risk for developing cancer, and tailoring interventions to accommodate pathogenesis, risk, and individual responses to interventions. This commentary will discuss how an investment in precision prevention research can accelerate cancer prevention agent development-the key to reducing cancer incidence and mortality.
© 2017 ASCPT.

Entities:  

Mesh:

Year:  2016        PMID: 28032900     DOI: 10.1002/cpt.566

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  3 in total

1.  Cancer Therapy: Shooting for the Moon.

Authors:  Jsh Lee; G M Blumenthal; R J Hohl; S-M Huang
Journal:  Clin Pharmacol Ther       Date:  2017-05       Impact factor: 6.875

2.  Meeting Report: Translational Advances in Cancer Prevention Agent Development Meeting.

Authors:  Mark Steven Miller; Peter J Allen; Powel H Brown; Andrew T Chan; Margie L Clapper; Roderick H Dashwood; Shadmehr Demehri; Mary L Disis; Raymond N DuBois; Robert J Glynn; Thomas W Kensler; Seema A Khan; Bryon D Johnson; Karen T Liby; Steven M Lipkin; Susan R Mallery; Emmanuelle J Meuillet; Richard B S Roden; Robert E Schoen; Zelton D Sharp; Haval Shirwan; Jill M Siegfried; Chinthalapally V Rao; Ming You; Eduardo Vilar; Eva Szabo; Altaf Mohammed
Journal:  J Cancer Prev       Date:  2021-03-30

Review 3.  Cancer prevention and screening: the next step in the era of precision medicine.

Authors:  Holli A Loomans-Kropp; Asad Umar
Journal:  NPJ Precis Oncol       Date:  2019-01-28
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.